祝贺！张文杰先生今日出任复宏汉霖高级副总裁兼首席商业运营官

官方发布

复宏汉霖宣布，张文杰先生于3月4日正式加入并出任公司高级副总裁兼首席商业运营官，负责公司整体商业规划和产品市场策略的制定，打造专业、高效的国际化商业运营团队。

张文杰先生

个人经历

张文杰先生在医药行业拥有逾25年的商业运营经验，曾先后出任拜耳先灵公司肿瘤特药事业部总监、罗氏中国第二事业部副总裁、安进公司日本及亚太区市场执行总监、安进公司中国区总经理等。他曾成功领导了多个品种中国市场的上市销售，包括多吉美、拜科奇、倍泰龙等，并拥有安维汀、特罗凯、美罗华等核心肿瘤产品中国市场的丰富管理经验，在公司产品线规划和多款核心肿瘤产品的市场策略方面取得了卓越成绩。

复宏汉霖联合创始人、总裁兼首席执行官刘世高博士对张文杰先生的加入表示欢迎和感谢。

近年来，复宏汉霖积极布局单抗生物药领域，产品已陆续进入临床开发后期和商业化生产阶段。伴随着公司产品的生产上市，复宏汉霖在产品的商业化运营方面大有可为！

张文杰先生表示：

国内新兴的生物制药公司发展迅猛，而复宏汉霖无论产品性、从技术能力、管理团队，以及复星国际强大的后盾力量，毫无疑问已经成为中国生物制药领域的领先者之一，且具有更远大的发展前景。非常荣幸有这个机会加入复宏汉霖，期待未来跟复宏汉霖的各位同事一起，把复宏汉霖打造成为世界上最领先的生物制药公司，惠及中国以及全球的更多患者。

复宏汉霖凭借高效和创新的自主核心竞争力，长期领跑中国单抗生物药行业。在创新不断升级的基础上，未来复宏汉霖也将在国际化运营上持续发力，全面打造从研发、生产、商业化的生物医药产业链平台。持续创新，卓越运营，致力于成为全球最受景仰的生物医药公司。

关于复宏汉霖

上海复宏汉霖生物技术股份有限公司由复星医药与海外科学家团队于2010年2月合资组建，公司主要致力于应用前沿技术进行生物类似药、生物改良药以及创新型单抗的研发及产业化，在中国上海、中国台北和美国加州均设有研发中心，产品覆盖肿瘤、自身免疫性疾病等领域。

截至目前，复宏汉霖13个产品、1个联合治疗方案已完成22项适应症的临床试验申请，累计获得全球范围内29个临床试验许可（中国大陆19个，中国台湾3个，美国3个，欧盟、澳大利亚、乌克兰和菲律宾各1个）。其中，公司首款重磅产品汉利康®（利妥昔单抗）已获国家药监局上市注册批准，成为首个获批上市的国产生物类似药。另一重磅产品HLX03也已获得国家药品监督管理局新药上市申请受理。

Official Announcement! Mr. WenjieZhang is appointed as SVP and CCO of Henlius

Henlius announced that Mr. Wenjie Zhang will officially join and serve as Senior Vice President (SVP) and Chief Commercial Operation Officer (CCO) of the company on March 4^th, responsible for the company's overall commercial planning and the formulation of product marketing strategy, to build a professional and efficient international commercial operation team.

Mr. Wenjie Zhang has more than 25 years of commercial operation experience in the pharmaceutical industry. He has successively served as the head of the oncology and specialty therapeutics business unit of Bayer Schering Pharma, Vice President of Business Unit 2 of Roche, Executive Director of Amgen Japan and Asia Pacific market, and General Manager of Amgen China, etc. Mr.Wenjie Zhang has successfully grew the Roche oncology portfolio including Avastin®(bevacizumab), Tarceva®(erlotinib) and Mabthera®(rituximab) in the China market and launched multiple products in China including Nexavar, Kogenate and Betaferon. He made outstanding achievements in pipeline planning, franchise strategy, and franchise marketing of multiple oncology products.

Dr. Scott Liu, Co-founder, President and Chief Executive officer of Henlius, welcomed and thanked Mr. Zhang for joining us. In recent years, Henlius has been actively involved in the field of monoclonal antibodies, and its products have successively reached the late stage of clinical development and commercial manufacturing. With the company's products being launched in the future, Henlius has great potential in the commercial operation of products!

“The emerging bio-pharmaceutical companies in China are developing rapidly, and there is no doubt that Henlius has become one of the leaders in domestic biopharmaceutical field with a more promising future, regardless of product quality, technical ability, management team, aswell as Fosun's powerful support.” said Mr. Wenjie Zhang, “I am very honored to have this opportunity to join Henlius, and I look forward to working with colleagues of Henlius in the future to build Henlius as a world's leading biopharmaceutical company, benefiting more patients in China and around the world.”

With its independent core competitiveness of high efficiency and innovation, Henlius has been leading the monoclonal antibody bio-pharmaceutical industry in China for a long time. On the basis of continuous innovation and upgrading, Henlius will also continue to make efforts in the international operation and build a biomedical industry chain platform from research, development, manufacturing and commercialization. We are doing continuous innovation, excellent operation and committed to become the world's most admired biomedical company.

About Henlius

Shanghai Henlius Biotech, Inc., a joint venture company co-founded by Fosun Pharma and a team of overseas scientists in February 2010, with its R&D footprint in Shanghai, Taipei, China and California, USA, specializes in the discovery, development, manufacturing and commercialization of high-quality biologics including biosimilar, bio-better and novel monoclonal antibody, to treat tumor and auto-immune disease.

Until now, Henlius has completed IND/CTA filings of 13 products and 1 combination therapy with 22 indications and obtained 29 successful IND/CTA approvals (19 approvals from China; 3 from the United States; 3 from Taiwan，China; each 1 from the European Union, Ukraine, Philippines and Australia). The first product of Henlius HLX01(rituximab injection) has granted approval by the China National Medical Products Administration (NMPA) as the first approved biosimilar in China and another important product of Henlius HLX03 has its New Drug Application under review. 

媒体联系人

周文婷：021-33395800*6093

陈迪：021-33395800*6053

邮箱：[e-mail]

来源：复宏汉霖

原文题目：官宣！张文杰先生将出任复宏汉霖高级副总裁兼首席商业运营官